ClinicalTrials.Veeva

Menu

Mepivacaine vs. Bupivacaine Spinal Anesthetic in Total Knee Arthroplasty

Henry Ford Health logo

Henry Ford Health

Status and phase

Completed
Phase 4

Conditions

Arthroplasty, Replacement, Knee
Ambulatory Surgical Procedures
Pain Management
Early Ambulation
Anesthesia, Spinal

Treatments

Drug: Mepivacaine
Drug: Bupivacaine

Study type

Interventional

Funder types

Other

Identifiers

Details and patient eligibility

About

The purpose of this study is to determine if a shorter-acting spinal anesthetic called mepivacaine has advantages over a longer-acting medication called bupivacaine.

Full description

Different medications last for different amounts of time and can be changed depending on the length of the procedure. A short acting spinal is generally used for procedures lasting less than 90 minutes. A longer acting medication would be any that lasts longer than 90 minutes. These medications not only block the signals that travel along the pain nerves, they also prevent the signals that tell the patients muscles to move. This means that after a total knee replacement a patient may delayed in their ability to get up and start walking early after surgery. Walking early in the recovery has been shown to decrease the rate of pulmonary embolism and death. Ambulating early is also important to prevent loss of strength, constipation, pneumonia and urinary retention.

Enrollment

32 patients

Sex

All

Ages

40 to 90 years old

Volunteers

Accepts Healthy Volunteers

Inclusion criteria

  • Adult patients undergoing primary total knee arthroplasty

Exclusion criteria

  • Chronic opioid users
  • Unable to give informed consent
  • Forego the use of a foley catheter
  • Those with hypersensitively to amide local anesthetics or opioids
  • Those with contraindications to spinal anesthesia
  • Conversion to general anesthesia will be excluded.

Trial design

Primary purpose

Treatment

Allocation

Randomized

Interventional model

Parallel Assignment

Masking

Quadruple Blind

32 participants in 2 patient groups

Mepivacaine Spinal Anesthetic
Experimental group
Description:
Mepivacaine 3 mL intrathecal injection of 2% solution
Treatment:
Drug: Mepivacaine
Bupivacaine Spinal Anesthetic
Active Comparator group
Description:
Bupivacaine 12 mg of 8.25% solution
Treatment:
Drug: Bupivacaine

Trial contacts and locations

1

Loading...

Data sourced from clinicaltrials.gov

Clinical trials

Find clinical trialsTrials by location
© Copyright 2024 Veeva Systems